On July 21, 2026, Mary Miller, serving as the Chief Legal Officer for Acrivon Therapeutics, Inc. (NASDAQ:ACRV), completed a transaction involving the sale of company equity. The total value of the disposed shares reached $1,008. This specific event was driven by the vesting of restricted stock units, which triggered mandatory tax withholding obligations. To fulfill these requirements, 573 shares were automatically sold at a execution price of $1.76 per share.
Following the completion of this sale, Ms. Miller's direct holding in Acrivon Therapeutics common stock stands at 82,194 shares. The transaction takes place against a backdrop of notable price movement for the biotech company. As of the reporting period, ACRV shares are trading at $1.67. This current valuation represents a decline of approximately 31% year-to-date. The stock has exhibited substantial volatility, with a recorded 52-week trading range spanning from $1.20 to $3.56. Recent intraday data shows the stock closing at $1.67, reflecting a minor decrease of $0.01 or 0.60% from the previous close of $1.68. After-hours trading activity indicates a slight further dip to $1.66, a decrease of $0.01 or 0.60%, recorded at 19:54:44.
Analysis from InvestingPro suggests that the stock may be undervalued at its current price levels. The platform provides additional insights for investors, including seven ProTips and comprehensive financial health metrics designed to offer a complete perspective on the biotech company's prospects.
In parallel with the insider transaction, Acrivon Therapeutics announced that its shareholders have approved amendments to the company's 2022 Equity Incentive Plan. These changes were ratified during the 2026 annual meeting. A primary component of the amendment is an increase in the number of shares available for equity awards by 3,000,000. This adjustment brings the total available share pool to 8,606,723 shares. Furthermore, the revised plan introduces an automatic annual increase in the share reserve, set to continue through 2032. This automatic increase is calculated at 5% of the company's fully diluted shares outstanding as of the prior December 31, unless the board decides to adjust it.
Market commentary also reflects ongoing analyst support for the company. Citizens has reiterated a Market Outperform rating for Acrivon Therapeutics, maintaining a $13.00 price target. This rating follows a strategic shift in the company's ACR-368 program, which now focuses on serous endometrial cancer. Citizens views this strategic pivot positively, highlighting the absence of a standard treatment for this condition as a favorable market factor.
These developments underscore Acrivon Therapeutics' ongoing strategic adjustments and its engagement with equity compensation structures. The combination of insider equity activity, governance updates, and analyst positioning provides a snapshot of the company's current operational and financial landscape.